Raphe Pharmaceutical Facial Hair Gel 13.9% Eflornithine HCL
A double-blind trial involving 594 female patients (393 received eflornithine, 201 received a placebo) tested the ability of eflornithine to reduce facial hair in women. Women in the study had to undergo hair removal at least twice weekly, as often as twice weekly, to participate.
Those with ingrown facial hair or androgen-mediated facial hair growth might find help in eflornithine. It addresses the differences in crushing a pill and avoiding crushing a pill.
Topical dermal studies of eflornithine reveal that eflornithine is not expected to cause contact sensitization, phototoxicity, or photosensitization in clinical use situations. Topical dermal study results for irritation revealed that eflornithine may cause irritation reactions in clinical use in susceptible individuals or in conditions of exaggerated use.
It is a cream gel containing 139 mg of eflornithine hydrochloride monohydrate per gram (13.9%) of anhydrous eflornithine hydrochloride.
Eflornithine hydrochloride is anhydrous monohydrate of (±) -2-difluoromethylornithine, with a molecular weight of 236.65.
It’s also composed of creareth-20; cetearyl alcohol; dimethicone; glyceryl stearate; methylparaben; mineral oil; PEG-100 stearate; phenoxyethanol; propylparaben; stearyl alcohol; and water.